Discriminating active from latent tuberculosis in patients presenting to community clinics

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Sandhu, Gurjinder ^a   Battaglia, Francesca ^b   Ely, Barry K ^b   Athanasakis, Dimitrios ^b   Montoya, Rosario ^d   Valencia, Teresa ^d   Gilman, Robert H ^c,d   Evans, Carlton A ^a,c,d   Friedland, Jon S ^a   Fernandez Reyes, Delmiro ^b   Agranoff, Daniel D ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMMUNITY CARE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PATTERN RECOGNITION; PERU; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS CONTROL; BLOOD; METABOLISM; OUTPATIENT DEPARTMENT;

ADULT; AMBULATORY CARE FACILITIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LATENT TUBERCULOSIS; MALE; PROTEOMICS;

EID: 84861590064     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038080     Document Type: Article

References (31)

1. WHO, (2008) Global Tuberculosis Control-Survelliance, Planning, Financing. Geneva World Health Organisation.
2. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
3. Young DB, Gideon HP, Wilkinson RJ, (2009) Eliminating latent tuberculosis. Trends Microbiol 17: 183-188.
4. Mathers CD, Lopez AD, CJL M, (2006) The Burden of Disease and Mortality by Condition: Data, Methods, and Results for 2001. In: Lopez AD, Mathers CD, ME, Jamison DT, CJLM, editors. Global Burden of Disease and Risk Factors: WHO.
5. Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, et al. (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845-855.
6. Syed Ahamed Kabeer B, Raman B, Thomas A, Perumal V, Raja A, (2010) Role of QuantiFERON-TB gold, interferon gamma inducible protein-10 and tuberculin skin test in active tuberculosis diagnosis. PLoS One 5: e9051.
7. Steingart KR, Henry M, Laal S, Hopewell PC, Ramsay A, et al. (2007) Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med 4: e202.
8. Engwegen JY, Gast MC, Schellens JH, Beijnen JH, (2006) Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 27: 251-259.
9. Zhang X, Guo T, Wang H, He W, Mei H, et al. (2008) Potential biomarkers of acute cerebral infarction detected by SELDI-TOF-MS. Am J Clin Pathol 130: 299-304.
10. Hong M, Zhang X, Hu Y, Wang H, He W, et al. (2009) The potential biomarkers for thromboembolism detected by SELDI-TOF-MS. Thromb Res 123: 556-564.
11. Pinet F, Beseme O, Cieniewski-Bernard C, Drobecq H, Jourdain S, et al. (2008) Predicting left ventricular remodeling after a first myocardial infarction by plasma proteome analysis. Proteomics 8: 1798-1808.
12. Agranoff D, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, et al. (2006) Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 368: 1012-1021.
13. Hodgetts A, Levin M, Kroll JS, Langford PR, (2007) Biomarker discovery in infectious diseases using SELDI. Future Microbiol 2: 35-49.
14. Papadopoulos MC, Abel PM, Agranoff D, Stich A, Tarelli E, et al. (2004) A novel and accurate test for Human African Trypanosomiasis. Lancet 363: 1358-1363.
15. Ren Y, He QY, Fan J, Jones B, Zhou Y, et al. (2004) The use of proteomics in the discovery of serum biomarkers from patients with severe acute respiratory syndrome. Proteomics 4: 3477-3484.
16. Sanghavi DM, Gilman RH, Lescano-Guevara AG, Checkley W, Cabrera LZ, et al. (1998) Hyperendemic pulmonary tuberculosis in a Peruvian shantytown. Am J Epidemiol 148: 384-389.
17. Kawai V, Soto G, Gilman RH, Bautista CT, Caviedes L, et al. (2006) Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg 75: 1027-1033.
18. Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, et al. (2006) Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 355: 1539-1550.
19. Cristianini N, Shawe-Taylor J, (2000) An Introduction to Support Vector Machines and other kernel-based learning methods: Cambridge University Press.
20. Guyon J, Weston S, Barnhill, Vapnik V, (2002) Gene selection for cancer classification using support vector machines. Machine Learning 46: 389-422.
21. Dye C, Williams BG, (2008) Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 5: 653-662.
22. Bamford AR, Crook AM, Clark JE, Nademi Z, Dixon G, et al. (2010) Comparison of interferon-{gamma} release assays and tuberculin skin test in predicting active tuberculosis (TB) in children in the UK: a paediatric TB network study. Arch Dis Child 95: 180-186.
23. Pai M, Riley LW, Colford JM Jr, (2004) Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systemic review. Lancet Infectious Diseases 4: 761-776.
24. Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, et al. (2011) Dominant TNF-alpha(+) Mycobacterium tuberculosis-specific CD4(+) T cell responses discriminate between latent infection and active disease. Nat Med 17: 372-376.
25. Wallis RS, Doherty TM, Onyebujoh P, Vahedi M, Laang H, et al. (2009) Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 9: 162-172.
26. Fung ET, Wright GL, Dalmasso EA, (2000) Proteomic strategies for biomarker identification: progress and challenges. Current Opinion in Molecular Therapeutics 2: 643-650.
27. Fung ET, (2010) A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 56: 327-329.
28. Administration USDaF (2009) FDA Clears a Test for Ovarian Cancer. U.S Drug and Food Adminitration.
29. Pang RT, Poon TC, Chan KC, Lee NL, Chiu RW, et al. (2006) Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. Clin Chem 52: 421-429.
30. Wu C, Wang Z, Liu L, Zhao P, Wang W, et al. (2009) Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma. J Gastroenterol Hepatol 24: 55-62.
31. Wu FX, Wang Q, Zhang ZM, Huang S, Yuan WP, et al. (2009) Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy. Cancer Lett 279: 163-170.